At 9.3% CAGR, the Europe Custom Antibody Services Market is Projected to be Worth US$ 395.31 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Europe custom antibody services market was valued at US$ 194.22 million in 2023 and is expected to reach US$ 395.31 million by 2031, registering a CAGR of 9.3% from 2023 to 2031. Rising approvals of biosimilars and rise in government research and development activities in emerging and developed economies are among the critical factors attributed to the Europe custom antibody services market expansion.

The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to introduce safe and effective biosimilars to the market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.

A few recent approvals of biosimilar products are mentioned below:

Biosimilars can reduce treatment costs and improve patient access to biologic therapies. In recent years, a vast range of biosimilars have been approved by the FDA. According to ScienceDirect.com, biosimilars can retain costs and expand the availability of monoclonal antibodies. Furthermore, in Europe, five rituximab biosimilars, six trastuzumab biosimilars, and eight bevacizumab biosimilars are available as anti-cancer drugs. Thus, the rising approvals of biosimilars fuel the growth of the custom antibody services market.

On the contrary, high costs and complexities associated with antibody production using transgenic animals hamper the growth of Europe custom antibody services market.

Based on product type, the Europe custom antibody services market is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. The monoclonal segment held 51.0% share of the Europe custom antibody services market in 2023, amassing US$ 99.05 million. It is projected to garner US$ 195.62 million by 2031 to expand at 8.9% CAGR during 2023–2031.

Based on service type, the Europe custom antibody services market is segmented into antibody discovery and development, antibody production services, and others. The antibody discovery and development segment held 70.4% share of the Europe custom antibody services market in 2023, amassing US$ 136.77 million. It is projected to garner US$ 280.90 million by 2031 to expand at 9.4% CAGR during 2023–2031.

Based on application, the Europe custom antibody services market is segmented into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment held 41.2% share of the Europe custom antibody services market in 2023, amassing US$ 79.99 million. It is projected to garner US$ 157.72 million by 2031 to expand at 8.9% CAGR during 2023–2031. 

Based on disease indication, the Europe custom antibody services market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. The oncology segment held 48.2% share of the Europe custom antibody services market in 2023, amassing US$ 93.54 million. It is projected to garner US$ 197.31 million by 2031 to expand at 9.8% CAGR during 2023–2031.

Based on source, the Europe custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. The mouse or humanized mice segment held 40.7% share of the Europe custom antibody services market in 2023, amassing US$ 78.99 million. It is projected to garner US$ 156.05 million by 2031 to expand at 8.9% CAGR during 2023–2031. The mouse or humanized mice segment is further sub segmented into monoclonal antibody platform, BsAB discovery platform, bispecific ADC platform, TCR-mimic antibody platform, Anti-GPCR antibody technology platform, and others.

Based on end user, the Europe custom antibody services market is segmented into life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. The life science industry segment held 36.7% share of the Europe custom antibody services market in 2023, amassing US$ 71.35 million. It is projected to garner US$ 143.65 million by 2031 to expand at 9.1% CAGR during 2023–2031.

Based on country, the Europe custom antibody services market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany held 29.3% share of Europe custom antibody services market in 2023, amassing US$ 56.98 million. It is projected to garner US$ 112.51 million by 2031 to expand at 8.9% CAGR during 2023–2031.

Key players operating in the custom antibody services market are Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc., among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com